LONA arrives at today's earnings release having shed nearly half its short interest since mid-April — a meaningful shift in the lending market that sets up an interesting read on positioning.
Short sellers have been pulling back sharply. At the April peak, short interest reached roughly 124,000 shares on April 20. By May 6 that had fallen to around 73,000 shares — a drop of more than 40% — bringing SI to just 1.8% of the free float. That is a low absolute level, but the direction of travel matters: bears who were pressing the stock hard a month ago have largely stepped back. Borrow availability has eased alongside this retreat, with the cost to borrow now running at 4.2% — down from a high of 7.5% in late March — confirming that the demand for short exposure has genuinely cooled.
The stock itself reflects the shifting mood. LONA closed at $9.86, up nearly 5% on the day and 8% on the week, even as the one-month return remains underwater at -10%. That combination — a down month followed by a sharp late bounce — frames today's print as a critical moment. The ORTEX short score is a middling 46, ranking in roughly the 42nd percentile for the sector, consistent with neither an extreme bear nor an extreme bull configuration. Options activity offers no additional signal; the put/call ratio has been effectively zero for weeks, suggesting minimal derivatives interest in either direction.
Ownership adds a layer of context worth noting. Perceptive Advisors, a specialist life-sciences fund, holds nearly 20% of shares — a level of concentrated institutional conviction that is uncommon for a name at this market cap stage. Several other investors, including TCG Crossover Management, Commodore Capital, and New Enterprise Associates, each hold close to 5%. These are not passive index holders; their presence implies a high-conviction view on the pipeline. The most recent insider activity, from early March, showed the CEO and other senior executives selling small amounts immediately after receiving stock awards — routine tax-related disposals rather than a directional bet, given the values involved ($5,000–$28,000).
Analyst coverage remains thin. Mizuho upgraded the stock to Outperform in February with a $10 price target — a target the stock has now surpassed. That note is more than 30 days old and the target has been exceeded, so it offers limited fresh guidance on where the Street sits today.
Past earnings prints have produced wide outcomes: a 12% single-day drop in March, a negligible move the prior quarter, and a 5-day gain of more than 25% after the most recent March release. LONA's history is one of high variance rather than consistent direction. Today's report will test whether the biotech's pipeline narrative — and whatever clinical or financial updates accompany the release — can sustain the late rebound or whether the stock reverts toward its one-month trend.
See the live data behind this article on ORTEX.
Open LONA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
